Patents by Inventor Joshua Ryan Clayton

Joshua Ryan Clayton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCOCORTICOID RECEPTOR AGONISTS
    Publication number: 20240018182
    Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
    Type: Application
    Filed: September 8, 2023
    Publication date: January 18, 2024
    Inventors: Adel Ahmed Rashad AHMED, Joshua Ryan CLAYTON, Jose Eduardo LOPEZ, William Thomas MCMILLEN, Ryan Edward STITES, Takako WILSON, Jacqueline Mary WURST
  • Glucocorticoid receptor agonists
    Patent number: 11787834
    Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: October 17, 2023
    Assignee: Eli Lilly and Company
    Inventors: Adel Ahmed Rashad Ahmed, Joshua Ryan Clayton, Jose Eduardo Lopez, William Thomas McMillen, Ryan Edward Stites, Takako Wilson, Jacqueline Mary Wurst
  • GLUCOCORTICOID RECEPTOR AGONISTS
    Publication number: 20220324904
    Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
    Type: Application
    Filed: March 22, 2022
    Publication date: October 13, 2022
    Inventors: Adel Ahmed Rashad AHMED, Joshua Ryan CLAYTON, Jose Eduardo LOPEZ, William Thomas McMILLEN, Ryan Edward STITES, Takako WILSON, Jacqueline Mary WURST
  • Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
    Patent number: 10344018
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, Daniel Jon Sall
  • Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
    Patent number: 10323019
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: June 18, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20190177300
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: February 12, 2019
    Publication date: June 13, 2019
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20180325873
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 15, 2018
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • JAK1 Inhibitors
    Publication number: 20170037034
    Abstract: The present invention relates to certain benzimidazole compounds, or pharmaceutically acceptable salts thereof, that inhibit Janus kinase 1 (JAK1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat certain types of cancer.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 9, 2017
    Inventor: Joshua Ryan Clayton
  • JAK1 inhibitors
    Patent number: 9556153
    Abstract: The present invention relates to certain benzimidazole compounds, or pharmaceutically acceptable salts thereof, that inhibit Janus kinase 1 (JAK1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat certain types of cancer.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 31, 2017
    Assignee: Eli Lilly and Company
    Inventor: Joshua Ryan Clayton
  • Inhibitor of JAK1 and JAK2
    Patent number: 9062050
    Abstract: The present invention provides an amino pyrazole compound, which is 3-[(1R)-6-fluoro-2,3-dihydro-1H-inden-1-yl]-N-(3-methyl-IH-pyrazol-5-yl)-3H-imidazo[4,5-b]pyridin-5-amine, or a pharmaceutically acceptable salt thereof, that inhibits JAK1 and JAK2 and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 23, 2015
    Assignee: ELI LILLY AND COMPANY
    Inventors: Timothy Paul Burkholder, Joshua Ryan Clayton
  • INHIBITOR OF JAK1 AND JAK2
    Publication number: 20150133490
    Abstract: The present invention provides an amino pyrazole compound, which is 3-[(1R)-6-fluoro-2,3-dihydro-1H-inden-1-yl]-N-(3-methyl-1H-pyrazol-5-yl)-3H-imidazo[4,5-b]pyridin-5-amine, or a pharmaceutically acceptable salt thereof, that inhibits JAK1 and JAK2 and, therefore may be useful in treating cancer.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 14, 2015
    Inventors: Timothy Paul Burkholder, Joshua Ryan Clayton
  • AKT inhibitors
    Patent number: 8436002
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: May 7, 2013
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, Jr., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • AKT INHIBITORS
    Publication number: 20120149684
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Application
    Filed: October 20, 2010
    Publication date: June 14, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, JR., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110294792
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Purine derivatives as kinase inhibitors
    Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110207721
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Amino pyrazole compound
    Patent number: 7897600
    Abstract: The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Timothy Paul Burkholder, Joshua Ryan Clayton, Liandong Ma
  • AMINO PYRAZOLE COMPOUND
    Publication number: 20100286139
    Abstract: The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.
    Type: Application
    Filed: December 8, 2009
    Publication date: November 11, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Timothy Paul Burkholder, Liandong Ma, Joshua Ryan Clayton
  • AMINO PYRAZOLE COMPOUND
    Publication number: 20100152181
    Abstract: The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.
    Type: Application
    Filed: December 8, 2009
    Publication date: June 17, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Timothy Paul Burkholder, Joshua Ryan Clayton, Liandong MA
  • Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors
    Patent number: 7666879
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander McLean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Mai Yip, Boyu Zhong